| 1. Khmelnitsky YL, Mozhaev VV, Cotterill IC, Michels PC, Boudjabi S, Khlebnikov V, Madhava Reddy M, Wagner GS, Hansen HC.. (2013) In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208)., 64 [PMID:23644195] [10.1016/j.ejmech.2013.03.062] |
| 2. Noguchi-Yachide T, Sakai T, Hashimoto Y, Yamaguchi T.. (2015) Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors., 23 (5): [PMID:25678016] [10.1016/j.bmc.2015.01.022] |
| 3. Baud MG, Lin-Shiao E, Zengerle M, Tallant C, Ciulli A.. (2016) New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition., 59 (4): [PMID:26367539] [10.1021/acs.jmedchem.5b01135] |
| 4. Xue X, Zhang Y, Liu Z, Song M, Xing Y, Xiang Q, Wang Z, Tu Z, Zhou Y, Ding K, Xu Y.. (2016) Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation., 59 (4): [PMID:26731490] [10.1021/acs.jmedchem.5b01511] |
| 5. Romero FA, Taylor AM, Crawford TD, Tsui V, Côté A, Magnuson S.. (2016) Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors., 59 (4): [PMID:26572217] [10.1021/acs.jmedchem.5b01514] |
| 6. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 7. Li J, Wang P, Zhou B, Shi J, Liu J, Li X, Fan L, Zheng Y, Ouyang L.. (2016) Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors., 121 [PMID:27266999] [10.1016/j.ejmech.2016.05.057] |
| 8. Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, Zhang S, Wang G, He G, Liu B.. (2017) Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer., 60 (24): [PMID:29172540] [10.1021/acs.jmedchem.7b00275] |
| 9. Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J.. (2017) Drug Discovery Targeting Bromodomain-Containing Protein 4., 60 (11): [PMID:28195723] [10.1021/acs.jmedchem.6b01761] |
| 10. Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L.. (2017) Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors., 27 (17): [PMID:28765013] [10.1016/j.bmcl.2017.07.054] |
| 11. Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J.. (2018) Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation., 151 [PMID:29649741] [10.1016/j.ejmech.2018.04.006] |
| 12. Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM.. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors., 26 (1): [PMID:29170024] [10.1016/j.bmc.2017.10.042] |
| 13. Law RP, Atkinson SJ, Bamborough P, Chung CW, Demont EH, Gordon LJ, Lindon M, Prinjha RK, Watson AJB, Hirst DJ.. (2018) Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain., 61 (10): [PMID:29656650] [10.1021/acs.jmedchem.7b01666] |
| 14. Unpublished dataset, |
| 15. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek. (2020) Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection, [10.21203/rs.3.rs-23951/v1] |
| 16. David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al. (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, [PMID:32353859] [10.1038/s41586-020-2286-9] |
| 17. Divakaran A, Talluri SK, Ayoub AM, Mishra NK, Cui H, Widen JC, Berndt N, Zhu JY, Carlson AS, Topczewski JJ, Schonbrunn EK, Harki DA, Pomerantz WCK.. (2018) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor., 61 (20): [PMID:30253095] [10.1021/acs.jmedchem.8b01248] |
| 18. Xing J, Zhang R, Jiang X, Hu T, Wang X, Qiao G, Wang J, Yang F, Luo X, Chen K, Shen J, Luo C, Jiang H, Zheng M.. (2019) Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors., 163 [PMID:30529546] [10.1016/j.ejmech.2018.11.018] |
| 19. Pan Z, Li X, Wang Y, Jiang Q, Jiang L, Zhang M, Zhang N, Wu F, Liu B, He G.. (2020) Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells., 63 (7): [PMID:32153186] [10.1021/acs.jmedchem.9b02178] |
| 20. Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.. (2020) Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain., 63 (10): [PMID:32324999] [10.1021/acs.jmedchem.0c00628] |
| 21. Jiang F, Hu Q, Zhang Z, Li H, Li H, Zhang D, Li H, Ma Y, Xu J, Chen H, Cui Y, Zhi Y, Zhang Y, Xu J, Zhu J, Lu T, Chen Y.. (2019) Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis., 62 (24): [PMID:31789032] [10.1021/acs.jmedchem.9b01010] |
| 22. Yu P, Liu W, Ren J, Wang Y, Ning Y, Huang M, Hu X, Wei L, Ji M, Cai J.. (2019) Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208., 29 (16): [PMID:31257080] [10.1016/j.bmcl.2019.06.028] |
| 23. Ma J, Chen H, Yang J, Yu Z, Huang P, Yang H, Zheng B, Liu R, Li Q, Hu G, Chen Z.. (2019) Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors., 27 (9): [PMID:30926312] [10.1016/j.bmc.2019.03.037] |
| 24. Rong J, Feng ZZ, Shi YJ, Ren J, Xu Y, Wang NY, Xue Q, Liu KL, Zhou SY, Wei W, Yu LT.. (2019) Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors., 29 (19): [PMID:31421967] [10.1016/j.bmcl.2019.07.036] |
| 25. Liu Z, Chen H, Wang P, Li Y, Wold EA, Leonard PG, Joseph S, Brasier AR, Tian B, Zhou J.. (2020) Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation., 63 (10): [PMID:32255647] [10.1021/acs.jmedchem.0c00035] |
| 26. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 27. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 28. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 29. Preston A,Atkinson S,Bamborough P,Chung CW,Craggs PD,Gordon L,Grandi P,Gray JRJ,Jones EJ,Lindon M,Michon AM,Mitchell DJ,Prinjha RK,Rianjongdee F,Rioja I,Seal J,Taylor S,Wall I,Watson RJ,Woolven J,Demont EH. (2020) Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins., 63 (17.0): [PMID:32691591] [10.1021/acs.jmedchem.0c00605] |
| 30. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 31. Liu Z, Li Y, Chen H, Lai HT, Wang P, Wu SY, Wold EA, Leonard PG, Joseph S, Hu H, Chiang CM, Brasier AR, Tian B, Zhou J.. (2022) Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site., 65 (3.0): [PMID:34982556] [10.1021/acs.jmedchem.1c01851] |
| 32. Carrasco K, Montersino C, Derviaux C, Saez-Ayala M, Hoffer L, Restouin A, Castellano R, Casassa J, Roche P, Pasquier E, Combes S, Morelli X, Collette Y, Betzi S.. (2022) CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation., 65 (7.0): [PMID:35348328] [10.1021/acs.jmedchem.1c02168] |
| 33. Lopes JR, Chiba DE, Dos Santos JL.. (2021) HIV latency reversal agents: A potential path for functional cure?, 213 [PMID:33540228] [10.1016/j.ejmech.2021.113213] |
| 34. Chen X, Meng F, Zhang J, Zhang Z, Ye X, Zhang W, Tong Y, Ji X, Xu R, Xu XL, You QD, Jiang ZY.. (2022) Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis., 238 [PMID:35544982] [10.1016/j.ejmech.2022.114423] |
| 35. Kong B, Zhu Z, Li H, Hong Q, Wang C, Ma Y, Zheng W, Jiang F, Zhang Z, Ran T, Bian Y, Yang N, Lu T, Zhu J, Tang W, Chen Y.. (2022) Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy., 227 [PMID:34731760] [10.1016/j.ejmech.2021.113953] |
| 36. Hu X, Zhang J, Zhang Y, Jiao F, Wang J, Chen H, Ouyang L, Wang Y.. (2022) Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities., 230 [PMID:34998039] [10.1016/j.ejmech.2021.114094] |
| 37. Li X, Liao J, Jiang Z, Liu X, Chen S, He X, Zhu L, Duan X, Xu Z, Qi B, Guo X, Tong R, Shi J.. (2020) A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years., 186 [PMID:31759729] [10.1016/j.ejmech.2019.111852] |
| 38. Ross J, Miron CE, Plescia J, Laplante P, McBride K, Moitessier N, Möröy T.. (2021) Targeting MYC: From understanding its biology to drug discovery., 213 [PMID:33460833] [10.1016/j.ejmech.2020.113137] |
| 39. Fu Y, Zhang Y, Sun H.. (2021) Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins., 226 [PMID:34547507] [10.1016/j.ejmech.2021.113853] |
